Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack study tests if one drug is enough before stent procedure

NCT ID NCT06710184

Disease control Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether using aspirin alone is as effective and safer than aspirin plus another blood thinner (fondaparinux) before a heart procedure in people with a type of heart attack called NSTEMI. About 5,000 participants will be randomly assigned to one of the two treatments and followed for 30 days. The goal is to see if aspirin alone can prevent death, new heart attacks, or urgent procedures while reducing the risk of severe bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 5,076 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of NSTEMI verified by: * Rise or/and fall in cardiac troponin (cTN) and * Symptoms of acute ischemia or ECG-changes compatible with acute ischemia. * Age above 18 years old * Expected remaining lifespan above 1 year * Informed consent Exclusion Criteria: * Treatment with any anticoagulants before enrollment and randomization * Including any direct anticoagulant (DOAC), LMWH, UFH or warfarin. * Not possible with CAG and PCI within 72 hours * Unsuitable for CAG and possible PCI due to poor condition * Estimated glomerular filtration rate (eGFR) \< 20 ml/min/1.73m2 * Known liver disease * Active bleeding or high risk of bleeding where treatment with Fondaparinux is contraindicated. * Anemia (B-Hemoglobin \< 6.0 mmol/l) * Pregnancy or breastfeeding * Endocarditis * Indication for acute CAG before enrollment and randomization: * ST-elevation Myocardial Infarction (STEMI) * Patients classified as "Very High Risk" according to ESC guidelines, defined as(1): * Hemodynamic instability (in need of inotropic support) or cardiogenic shock (DANGER-SHOCK criteria (20)) at time of admission. * Acute heart failure because of presumed acute ischemia * Life-threatening arrhythmias or cardiac arrest * Mechanical complications (such as papillary muscle rupture with acute mitral regurgitation, free wall rupture and interventricular rupture)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction acute subendocardial myocardial infarction ischemic disease myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI) Nstemi - non-ST segment elevation myocardial infarction (MI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg Universitetshospital

    NOT_YET_RECRUITING

    Aalborg, Region Nord, 9000, Denmark

  • Aarhus University Hospital, Department of Cardiology

    RECRUITING

    Aarhus N, 8200, Denmark

  • Esbjerg Sygehus

    NOT_YET_RECRUITING

    Esbjerg, Region Syd, 6700, Denmark

  • Odense Universitetshospital

    RECRUITING

    Odense, Region Syd, 5000, Denmark

  • Regionshospitalet Gødstrup

    RECRUITING

    Herning, Region Midt, 7400, Denmark

  • Regionshospitalet Horsens

    NOT_YET_RECRUITING

    Horsens, Region Midt, 8700, Denmark

  • Regionshospitalet Viborg

    RECRUITING

    Viborg, Region Midt, Denmark

  • Sygehus Lillebælt, Kolding

    RECRUITING

    Kolding, Region Syd, 6000, Denmark

  • Sygehus Lillebælt, Vejle

    RECRUITING

    Vejle, Region Syd, 7100, Denmark

  • Sygehus Søndejylland, Aabenraa

    RECRUITING

    Aabenraa, Region Syd, 6200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.